ABN Amro Investment Solutions Acquires Shares of 12,904 CVS Health Corporation $CVS

ABN Amro Investment Solutions bought a new position in CVS Health Corporation (NYSE:CVS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,904 shares of the pharmacy operator’s stock, valued at approximately $890,000.

Several other large investors have also recently modified their holdings of CVS. Goldman Sachs Group Inc. increased its stake in CVS Health by 87.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after purchasing an additional 4,632,530 shares in the last quarter. Dodge & Cox grew its holdings in shares of CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after buying an additional 3,353,223 shares during the last quarter. Nuveen LLC bought a new stake in shares of CVS Health during the first quarter valued at approximately $204,421,000. Invesco Ltd. raised its holdings in CVS Health by 13.2% in the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after acquiring an additional 2,375,764 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its position in CVS Health by 815.2% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after acquiring an additional 2,372,121 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on CVS. Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a report on Tuesday. Barclays lifted their price objective on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Raymond James Financial upped their target price on shares of CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. Jefferies Financial Group lifted their price target on shares of CVS Health from $92.00 to $98.00 in a research note on Thursday, October 30th. Finally, Wells Fargo & Company lowered their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $89.41.

Insider Activity at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.22% of the company’s stock.

CVS Health Stock Down 1.7%

CVS opened at $77.86 on Friday. The stock has a market cap of $98.84 billion, a price-to-earnings ratio of 204.90, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. The firm’s fifty day moving average is $77.70 and its 200 day moving average is $69.90. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is 700.00%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.